6 completed, 2 active not recruiting, 2 unknown, 1 not yet recruiting. 4 Phase 2, 2 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Tadalafil 20 MG: new trials by email Literature Review of Tadalafil 20 MG trials Research Report on Tadalafil 20 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction IncobotulinumtoxinA (100 Units), Placebo, Tadalafil 20 MG - Erectile Dysfunction | Phase 2 | Not yet recruiting | Northwestern University | 30 | 2026-09-01 | 2026-08-14 |
| Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer Tadalafil 20 MG - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Active not recruiting | University of Arizona | 11 | 2023-04-20 | 2026-07-02 |
| Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial Tadalafil 20 MG, Placebo - Cerebral Small Vessel Diseases, Stroke, Ischemic | Phase 2 | Active not recruiting | Christina Kruuse | 100 | 2022-05-31 | 2024-12-09 |
| A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC - Healthy | Phase 1 | Completed | Actelion | 40 | 2022-02-04 | 2025-03-30 |
| A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil FDC of macitentan/tadalafil (10 mg/20 mg), Macitentan 10 mg, Tadalafil 20 mg - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 18 | 2021-04-30 | 2025-03-30 |
| Effect of PDE5 Inhibition on Adipose Metabolism in Humans Tadalafil 20 MG, Placebo - Obesity | Phase 2 | Completed | Vanderbilt University Medical Center | 99 | 2021-03-16 | 2026-07-30 |
| Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg Tadalafil 20 MG - Erectile Dysfunction Following Radical Prostatectomy | Completed | Federico II University | 40 | 2020-07-04 | 2021-09-24 | |
| Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg for More Than 6 Months Tadalafil 20 MG - Erectile Dysfunction Following Radical Prostatectomy | Completed | Federico II University | 54 | 2019-11-01 | 2020-07-29 | |
| Effect of Tadalafil Administration on Vasodilatation Mediated by Flow in Patients With Obesity Grade I-II Tadalafil 20 MG - Obesity and Erectile Dysfuntion | Phase 3 | Unknown | Centro Universitario de Ciencias de la Salud, Mexico | 80 | 2019-05-01 | 2019-04-05 |
| The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy Tadalafil 20 MG, beetroot juice extract - Muscular Dystrophy | Early Phase 1 | Terminated | Cedars-Sinai Medical Center | 6 | 2017-11-01 | 2020-01-14 |
| Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function Tadalafil 20 MG, Placebo 20 MG - Heart Defects, Congenital, Transposition of Great Vessels With Ventricular Inversion | Phase 3 | Completed | Insel Gruppe AG, University Hospital Bern | 100 | 2017-10-25 | 2023-06-23 |
| Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment Sildenafil 100 mg, Tadalafil 20 mg, Combination half of maximal dose for sildenafil & tadalafil - Erectile Dysfunction | Phase 4 | Unknown | Rambam Health Care Campus | 30 | 2011-06-01 | 2011-06-20 |
Erectile Dysfunction (2) · Obesity (2) · Cerebral Small Vessel Diseases (1) · Congenitally Corrected Transposition of the Great Arteries (1) · Heart Defects, Congenital (1) · Ischemic Stroke (1) · Muscular Dystrophies (1) · Muscular Dystrophy, Duchenne (1)
Federico II University (2) · Actelion (1) · Cedars-Sinai Medical Center (1) · Centro Universitario de Ciencias de la Salud, Mexico (1) · Christina Kruuse (1) · Insel Gruppe AG, University Hospital Bern (1) · Janssen Research & Development, LLC (1) · Northwestern University (1) · Rambam Health Care Campus (1) · University of Arizona (1) · Vanderbilt University Medical Center (1)
United States (4) · Italy (2) · Austria (1) · Belgium (1) · Denmark (1) · Israel (1) · Mexico (1) · Switzerland (1)
Gilda Cennamo (2) · Christina Kruuse, MD, Prof (1) · Evan Brittain, MD, MSci (1) · Junaid Arshad, MD (1) · Markus Schwerzmann, MD (1) · Ronald G Victor, MD (1) · Yoram Vardi, Prof. (1)
PMID 16765134, PMID 17210844, PMID 17606845, PMID 22192662, PMID 23067916, PMID 23247302, PMID 23790549, PMID 23972966, PMID 24589851, PMID 24644309, PMID 26185211, PMID 28566262, PMID 37264734, PMID 38726920, PMID 39210472, PMID 40470125, PMID 40718899, PMID 41332889